Chlorine dioxide

CASRN 10049-04-4

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (25 pp, 177 K) last updated: 10/12/2000

RfD (mg/kg-day) System Basis PoD Composite UF Confidence
3 x10-2 Nervous, Developmental Neurodevelopmental effects NOAEL : 3
mg/kg-day
100 Medium/High

Reference Concentration for Inhalation Exposure (RfC) (PDF) (25 pp, 177 K) last updated: 10/12/2000

RfC (mg/m3) System Basis PoD Composite UF Confidence
2 x10-4 Respiratory, Cardiovascular Vascular congestion and peribronchial edema LOAEL (HEC): 6.4 x10-1
mg/m3
3000 Low

Cancer Assessment


Weight of Evidence for Cancer (PDF) (25 pp, 177 K) last updated: 10/12/2000

WOE Characterization Framework for WOE Characterization
D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Carcinogenic potential cannot be determined Proposed Guidelines for Carcinogen Risk Assessment (US EPA, 1996)
Basis:
  • Under the current guidelines (U.S. EPA, 1986), chlorine dioxide is classified as Group D; not classifiable as to human carcinogenicity because of inadequate data in humans and animals. Under the draft Carcinogen Assessment Guidelines (U.S. EPA, 1996), the human carcinogenicity of chlorine dioxide cannot be determined because no satisfactory human or animal studies assessing the chronic carcinogenic potential of chlorine dioxide have been located.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (25 pp, 177 K)

Not assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (25 pp, 177 K)

Not assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.